ProofPilot Acquires Lokavant to Enhance Clinical Trial Analytics
ProofPilot has acquired Lokavant, a leader in clinical trial intelligence, to integrate predictive analytics into its platform, announced in a press release. This acquisition aims to combine ProofPilot's trial execution capabilities with Lokavant's advanced analytics, offering a comprehensive solution for optimizing clinical research.
Lokavant, spun out of Roivant in 2020, uses historical and real-time data to provide predictive insights and improve study feasibility. By integrating these capabilities, ProofPilot enhances its platform, allowing sponsors and CROs to anticipate challenges and drive faster, more reliable outcomes.
The combined platform offers AI-powered study forecasting, real-time performance dashboards, and enhanced study oversight capabilities. This integration is designed to improve operational predictability, reduce risk, and ensure trials generate reliable results, ultimately accelerating the delivery of new therapies to patients.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
TRI Launches TRIAL.OS for Clinical Trial Management
AbbVie Partners With Valkai on AI Tools for Clinical Development
Phylo Launches Target Atlas for Drug Target Prioritization
TRI adds AI risk assessment to OPRA clinical trial platform
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Daily AI Brief: the AI news that matters, in your inbox.